Wei Wang1, Chen Wang1, D Brian Dawson1, Erik C Thorland1, Patrick A Lundquist1, Bruce W Eckloff1, Yanhong Wu1, Saurabh Baheti1, Jared M Evans1, Steven S Scherer1, Peter J Dyck1, Christopher J Klein2. 1. From the Departments of Neurology, Peripheral Nerve Division (W.W., P.J.D., C.J.K.), Department of Health Science Research (C.W., S.B., J.M.E.), Laboratory Medicine and Pathology (D.B.D., E.C.T., P.A.L., Y.W., C.J.K.), Medical Genome Facility (B.W.E., Y.W.), and Medical Genetics (C.J.K., D.B.D.), Mayo Clinic, Rochester, MN; Department of Neurology (W.W.), China-Japan Friendship Hospital, Beijing, China; and Department of Neurology (S.S.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. 2. From the Departments of Neurology, Peripheral Nerve Division (W.W., P.J.D., C.J.K.), Department of Health Science Research (C.W., S.B., J.M.E.), Laboratory Medicine and Pathology (D.B.D., E.C.T., P.A.L., Y.W., C.J.K.), Medical Genome Facility (B.W.E., Y.W.), and Medical Genetics (C.J.K., D.B.D.), Mayo Clinic, Rochester, MN; Department of Neurology (W.W.), China-Japan Friendship Hospital, Beijing, China; and Department of Neurology (S.S.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. klein.christopher@mayo.edu.
Abstract
OBJECTIVE: To assess the efficiency of target-enrichment next-generation sequencing (NGS) with copy number assessment in inherited neuropathy diagnosis. METHODS: A 197 polyneuropathy gene panel was designed to assess for mutations in 93 patients with inherited or idiopathic neuropathy without known genetic cause. We applied our novel copy number variation algorithm on NGS data, and validated the identified copy number mutations using CytoScan (Affymetrix). Cost and efficacy of this targeted NGS approach was compared to earlier evaluations. RESULTS: Average coverage depth was ∼760× (median = 600, 99.4% > 100×). Among 93 patients, 18 mutations were identified in 17 cases (18%), including 3 copy number mutations: 2 PMP22 duplications and 1 MPZ duplication. The 2 patients with PMP22 duplication presented with bulbar and respiratory involvement and had absent extremity nerve conductions, leading to axonal diagnosis. Average onset age of these 17 patients was 25 years (2-61 years), vs 45 years for those without genetic discovery. Among those with onset age less than 40 years, the diagnostic yield of targeted NGS approach is high (27%) and cost savings is significant (∼20%). However, the cost savings for patients with late onset age and without family history is not demonstrated. CONCLUSIONS: Incorporating copy number analysis in target-enrichment NGS approach improved the efficiency of mutation discovery for chronic, inherited, progressive length-dependent polyneuropathy diagnosis. The new technology is facilitating a simplified genetic diagnostic algorithm utilizing targeted NGS, clinical phenotypes, age at onset, and family history to improve diagnosis efficiency. Our findings prompt a need for updating the current practice parameters and payer guidelines.
OBJECTIVE: To assess the efficiency of target-enrichment next-generation sequencing (NGS) with copy number assessment in inherited neuropathy diagnosis. METHODS: A 197 polyneuropathy gene panel was designed to assess for mutations in 93 patients with inherited or idiopathic neuropathy without known genetic cause. We applied our novel copy number variation algorithm on NGS data, and validated the identified copy number mutations using CytoScan (Affymetrix). Cost and efficacy of this targeted NGS approach was compared to earlier evaluations. RESULTS: Average coverage depth was ∼760× (median = 600, 99.4% > 100×). Among 93 patients, 18 mutations were identified in 17 cases (18%), including 3 copy number mutations: 2 PMP22 duplications and 1 MPZ duplication. The 2 patients with PMP22 duplication presented with bulbar and respiratory involvement and had absent extremity nerve conductions, leading to axonal diagnosis. Average onset age of these 17 patients was 25 years (2-61 years), vs 45 years for those without genetic discovery. Among those with onset age less than 40 years, the diagnostic yield of targeted NGS approach is high (27%) and cost savings is significant (∼20%). However, the cost savings for patients with late onset age and without family history is not demonstrated. CONCLUSIONS: Incorporating copy number analysis in target-enrichment NGS approach improved the efficiency of mutation discovery for chronic, inherited, progressive length-dependent polyneuropathy diagnosis. The new technology is facilitating a simplified genetic diagnostic algorithm utilizing targeted NGS, clinical phenotypes, age at onset, and family history to improve diagnosis efficiency. Our findings prompt a need for updating the current practice parameters and payer guidelines.
Authors: Kevin Garofalo; Anke Penno; Brian P Schmidt; Ho-Joon Lee; Matthew P Frosch; Arnold von Eckardstein; Robert H Brown; Thorsten Hornemann; Florian S Eichler Journal: J Clin Invest Date: 2011-12 Impact factor: 14.808
Authors: E Matthew Hoffman; Nathan P Staff; Jared M Robb; Jennifer L St Sauver; Peter J Dyck; Christopher J Klein Journal: Neurology Date: 2015-04-01 Impact factor: 9.910
Authors: Jianying Huang; Chongyang Han; Mark Estacion; Dymtro Vasylyev; Janneke G J Hoeijmakers; Monique M Gerrits; Lynda Tyrrell; Giuseppe Lauria; Catharina G Faber; Sulayman D Dib-Hajj; Ingemar S J Merkies; Stephen G Waxman Journal: Brain Date: 2014-04-27 Impact factor: 13.501
Authors: J D England; G S Gronseth; G Franklin; G T Carter; L J Kinsella; J A Cohen; A K Asbury; K Szigeti; J R Lupski; N Latov; R A Lewis; P A Low; M A Fisher; D N Herrmann; J F Howard; G Lauria; R G Miller; M Polydefkis; A J Sumner Journal: Neurology Date: 2008-12-03 Impact factor: 9.910
Authors: J D England; G S Gronseth; G Franklin; G T Carter; L J Kinsella; J A Cohen; A K Asbury; K Szigeti; J R Lupski; N Latov; R A Lewis; P A Low; M A Fisher; D Herrmann; J F Howard; G Lauria; R G Miller; M Polydefkis; A J Sumner Journal: Muscle Nerve Date: 2009-01 Impact factor: 3.217
Authors: R A C Hughes; T Umapathi; I A Gray; N A Gregson; M Noori; A S Pannala; A Proteggente; A V Swan Journal: Brain Date: 2004-06-16 Impact factor: 13.501
Authors: V Fridman; B Bundy; M M Reilly; D Pareyson; C Bacon; J Burns; J Day; S Feely; R S Finkel; T Grider; C A Kirk; D N Herrmann; M Laurá; J Li; T Lloyd; C J Sumner; F Muntoni; G Piscosquito; S Ramchandren; R Shy; C E Siskind; S W Yum; I Moroni; E Pagliano; S Zuchner; S S Scherer; M E Shy Journal: J Neurol Neurosurg Psychiatry Date: 2014-11-27 Impact factor: 10.154
Authors: Christopher J Klein; Yanhong Wu; Mark E Jentoft; Georges Mer; Robert J Spinner; P James B Dyck; Peter J Dyck; Michelle L Mauermann Journal: Ann Neurol Date: 2017-01-28 Impact factor: 10.422
Authors: Tanya M Bardakjian; Ingo Helbig; Colin Quinn; Lauren B Elman; Leo F McCluskey; Steven S Scherer; Pedro Gonzalez-Alegre Journal: Neurogenetics Date: 2018-03-28 Impact factor: 2.660